Weekly Digest - June 2025

Weekly Digest - June 2025

16 June 2025: Debiopharm’s ADC research gains momentum with launch of first-in-human trial assessing Debio 1562M in acute myeloid leukemia patients

  • Debiopharm has dosed the first patient in a Phase 1/2 first-in-human trial of Debio 1562M, a novel ADC targeting CD37 in relapsed/refractory AML patients
  • Debio 1562M combines Naratuximab (anti-CD37 mAb), multilink linker, and a microtubule inhibitor payload, and has shown broad and superior anti-leukemic activity in preclinical models
  • Debiopharm highlights its decade-long investment in ADC technology and expresses hope that Debio 1562M could transform AML treatment by offering a more precise and tolerable option

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home